TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03823586

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaire AQUA©, pediatric version
Description: A version of AQUA© recently adapted and pretested in young athletes. It is a self-administered questionnaire composed of 25 items includes items about type, duration and intensity of training sessions, allergic status, habits of children (supplements and drugs intake) and their parents (smoking), presence and burden of infections.

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaire AQUA©, pediatric version
Description: A version of AQUA© recently adapted and pretested in young athletes. It is a self-administered questionnaire composed of 25 items includes items about type, duration and intensity of training sessions, allergic status, habits of children (supplements and drugs intake) and their parents (smoking), presence and burden of infections.
Study: NCT00568594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL180

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02445729

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dressing removal at 24 hours
Description: Dressing will be removed 24 hours after cesarean section and wounds will be assessed for healing and presence of infection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dressing removal at 48 hours
Description: Dressing will be removed 48 hours after cesarean section and wounds will be assessed for healing and presence of infection.
Study: NCT00422877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxoprexin
Description: DHA-paclitaxel
Study: NCT04488081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: oral, 30 mg bid × 14 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dornase alfa
Description: For Non-intubated subjects: 2.5 mg BID until hospital discharge, improvement to room air (or baseline oxygen use prior to illness) for 24 hours, or total of 14 days of study drug, whichever comes first.~For intubated subjects: 5.0 mg BID in 10 mL normal saline until extubation or 14 days, whichever comes first. If intubated for less than 14 days, extubated subjects received 2.5 mg BID for a total Dornase treatment of 14 days, or until hospital discharge, whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Oral: 400 mg BID for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Oral: High dose 80 mg QID for 7 days followed by 40 mg BID for a course of 14 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC14
Description: intravenous, 4 mg/kg on day 1, followed by 2 mg/kg on days 2, 3, 4
Study: NCT01284920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDV3100
Description: oral
Study: NCT02831127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: short message service group
Description: Each month after stent implantation, the investigator sent a text message by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date to come back to the hospital for stent management. Patients were requested to respond by SMS and were encouraged to contact the investigator if they had any questions about stent management. Besides, patients received conventional reminder:After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional group
Description: After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
Study: NCT02381314

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: enoblituzumab plus ipilimumab
Description: enoblituzumab is administered by IV infusion once per week. Ipilimumab is administered by IV infusion every 3 weeks for up to 4 doses.
Study: NCT03705559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized Marijuana
Description: Active Marijuana or Placebo, administered through vaporizer
Study: NCT04488081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aviptadil
Description: Inhalation via nebulizer, 100 µg three times (TID) daily for a maximum of 14 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: narsoplimab
Description: Dosed at 4 mg/kg, given as a 30-minute intravenous infusion (up to a maximum of 370 mg per infusion) twice weekly for a total of four weeks (i.e. 9 doses) or until hospital discharge whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Description: 4 mg tablet, with dosing regimen of 8 mg every 8 hours daily for ten (10) days. If the patient weighs less than 48 kg, the regimen is 6 mg every 8 hours daily for ten (10) days. If the participant was discharged before completion of this dosing regimen the drug was not continued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Modified CsA at an oral dose of 5mg/kg per day administered in two divided doses daily for 5-days.
Study: NCT04138212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel, Cisplatin
Description: Paclitaxel 175mg/m2 plus Cisplatin 75mg/m2, q21d, 2 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiation therapy
Description: Paclitaxel 50mg/m2 plus Carboplatin AUC=2, q1w, 5 cycles; 41.4Gy, 1.8Gy/d\*23
Study: NCT03705559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized Marijuana
Description: Active Marijuana or Placebo, administered through vaporizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Agonist
Description: Active Opioid Agonist or Placebo, administered intranasally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Agonist
Description: Active Opioid Agonist or Placebo, administered intranasally
Study: NCT00739310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vest Treatment (high frequency chest wall oscillation)
Description: twice daily for 15-20 minutes
Study: NCT02180685

Intervention type: OTHER
Group type: OTHER
Intervention: Anchor fixation

Intervention type: OTHER
Group type: OTHER
Intervention: Anchor fixation
Study: NCT04154644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoPop
Description: The new CryoPop device will be tested on women with abnormal cytology. Benchmark testing occurred in the previous study and CryoPop was found to be non-inferior to standard cryotherapy device (MedGyn) in woman with normal cytology.
Study: NCT01094977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 10 mg/kg bolus with a 5 mg/kg/h infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 100 mg/kg bolus with a 10 mg/kg/h infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Study: NCT01215669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDflu™: Split virion inactivated influenza vaccine
Description: Single dose 0.1 mL, intradermal
Study: NCT00235183

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plasma
Description: transfusion of more than 15 mL/Kg of plasma

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plasma
Description: transfusion of more than 15 mL/Kg of plasma
Study: NCT01215669

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip®: Split virion inactivated influenza vaccine
Description: Single dose 0.5 mL, intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDflu™: Split virion inactivated influenza vaccine
Description: Single dose 0.1 mL, intradermal

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip®: Split virion inactivated influenza vaccine
Description: Single dose 0.5 mL, intramuscular
Study: NCT02741089

Intervention type: PROCEDURE
Intervention: Indication for a flexible bronchoscopy
Description: The data of patients are collected within the hospital routine documentation during the flexible bronchoscopy. The bronchoscopy is performed regardless of this study. Following the bronchoscopy the patients are asked a few questions about their health and their perception.~The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient.
Study: NCT03107598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colloid preload
Description: coparaison between colloid and crystalloide loading in spinal anesthesia for cesarean section

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: colloid preload
Description: coparaison between colloid and crystalloide loading in spinal anesthesia for cesarean section
Study: NCT01616784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSII (Insulin Pump) plus DAFNE
Description: Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
Study: NCT01680497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crosslinked hyaluronic acid dermal filler
Description: All treatment details are at the discretion of the Investigator and should be guided by the Directions for Use. Up to 3 treatments will be administered: Initial treatment, optional top-up treatment at Day 14 post-initial treatment, and optional repeat treatment at Month 12 post-initial treatment.
Study: NCT01193127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS302 Solution
Study: NCT01616784

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MDI (levemir® & quick acting insulin) plus DAFNE
Description: Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
Study: NCT02658981

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-LAG-3 Monoclonal Antibody BMS 986016
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-LAG-3 Monoclonal Antibody BMS 986016
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-LAG-3 Monoclonal Antibody BMS 986016
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD-1
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD-1
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD-1
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative Studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative Studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative Studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD137
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD137
Description: Given IV
Study: NCT01193127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS302 Mydriatic Solution
Study: NCT02658981

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD137
Description: Given IV
Study: NCT01180764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza (Omega-3 acid ethyl esters)
Description: 1g capsules, 4 capsules po daily
Study: NCT01193127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS302 Anti-inflammatory Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Balanced Salt Solution (BSS) Solution
Study: NCT01180764

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching active lovaza, 1 g capsules, 4 capsules po daily
Study: NCT01334983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REST
Description: Instruction in an individualized rapid easy strength training (isotonic with therabands) and pedometer-based walking programs.
Study: NCT03226548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paycheck Plus
Description: A four-fold increase in the Earned Income Tax Credit
Study: NCT01647425

Intervention type: BEHAVIORAL
Intervention: physician assessment
Description: * Socio-economic conditions and general features: educational level, professional status...~* Assessment of current and past use of tobacco: current smoking status reported by the patient; in lifelong non-smokers: previous history of passive smoking reported by the patient; breath carbon monoxide level; in past smokers: age of first cigarette, total reported duration of active smoking, breath carbon monoxide level...~* in current smokers: age of first tobacco use, total reported duration of active smoking; Fagerström Nicotine Dependence Test...~* Assessment of the current and past uses of alcohol: previous-year assessment using the CAGE questionnaire and the AUDIT Test; average weekly alcohol consumption over the last 12 months...~* Assessment of current use of cannabis using the Cannabis Abuse Screening Test~* Psychiatric assessment using the MINI 5.0
Study: NCT00054444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride Liposomes
Description: Given IV
Study: NCT00796263

Intervention type: DRUG
Group type: OTHER
Intervention: HAART
Description: 2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications or Kivexa (ABC300/3TC300) orally once daily~Dolutegravir(DTG) 50 mg orally once daily
Study: NCT01197755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: fostamatinib 100 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: fostamatinib 100 mg twice daily/150 mg once daily
Study: NCT00054444

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT00116987

Intervention type: DEVICE
Group type: OTHER
Intervention: Dual chamber cardiac pacemaker
Description: Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.

Intervention type: DEVICE
Group type: OTHER
Intervention: Single chamber cardiac pacemaker
Description: Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
Study: NCT01197755

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo twice daily
Study: NCT00416884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: 30 mg on day -8 over 5-6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m\^2 on day -4 through day -2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-Cell Deplete
Description: Stem cells will be T cell depleted and given on day 0
Study: NCT02015559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mucoadhesive oral wound rinse
Description: Given PO
Study: NCT00235183

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plasma
Description: transfusion of more than 15 mL/Kg of plasma
Study: NCT02015559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01685411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Day -8 (prior to transplant): Per institutional guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keppra
Description: Day -8 (prior to transplant): Per institutional guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Days -7 through -4 (prior to transplant): given intravenously (IV) infusion over 2 hours every 6 hours following dose, administration and pharmacokinetic monitoring per University of Minnesota institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -3 and -2 (prior to transplantation): given as a 2 hour intravenous infusion with a high volume fluid flush and mesna per institutional guidelines. Dosing is based on actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: All patients (regardless of allograft source) will receive tacrolimus therapy beginning on day -3. Dosing will be monitored and altered as clinically appropriate per institutional pharmacy guidelines. Dose adjustments will be made on the basis of toxicity and/or low tacrolimus levels. Taper at day +100 for matched sibling donor (MSD) recipients, and day +180 for non-MSD recipients. Taper to zero by 10% weekly dose reduction over approximately 10 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Day -3 (prior to transplant): Recipients of umbilical cord blood will given a dose of 3 gm/day every 8 or 12 hours (\> or = 40 kg) or 15 mg/kg 3 times per day (\< 40 kg) for up to 30 days unless no engraftment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplant
Description: Day 0 (or Day+1/+2 to accommodate weekdays): Infusion of cells from related or unrelated donor bone marrow or single or double unrelated donor umbilical cord blood.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Beginning Day +1: Intravenously (IV) 5 mcg/kg once daily and continuing until the absolute neutrophil count is \>2500 x 10\^9/L or per institutional guidelines.
Study: NCT02920307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TEP without fixation
Description: Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEP with fixation
Description: Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAPP without fixation
Description: Standard transabdominal preperitoneal (TAPP) inguinal hernia repair without mesh fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAPP with fixation
Description: Standard transabdominal preperitoneal (TAPP) inguinal hernia repair
Study: NCT02137447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure treatment
Study: NCT01635998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Vessix Renal Denervation System
Description: Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts
Study: NCT00004891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radionuclide imaging

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01654874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-MIP-1404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-MIP-1404
Study: NCT01072448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 75 μg
Description: Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
Study: NCT04361448

Intervention type: OTHER
Group type: OTHER
Intervention: samling of oropharynx and nasopharynx
Description: Three different swabs will be taken of each participant: 1 oropharyngeal swab and 2 nasopharyngeal swabs
Study: NCT04075305

Intervention type: RADIATION
Intervention: Radiation therapy
Description: Radiation therapy on the CE marked and FDA approved MR-Linac

Intervention type: RADIATION
Intervention: Radiation therapy
Description: Radiation therapy on the CE marked and FDA approved MR-Linac

Intervention type: RADIATION
Intervention: Radiation therapy
Description: Radiation therapy on the CE marked and FDA approved MR-Linac

Intervention type: RADIATION
Intervention: Radiation therapy
Description: Radiation therapy on the CE marked and FDA approved MR-Linac

Intervention type: RADIATION
Intervention: Radiation therapy
Description: Radiation therapy on the CE marked and FDA approved MR-Linac

Intervention type: RADIATION
Intervention: Radiation therapy
Description: Radiation therapy on the CE marked and FDA approved MR-Linac

Intervention type: RADIATION
Intervention: Radiation therapy
Description: Radiation therapy on the CE marked and FDA approved MR-Linac

Intervention type: RADIATION
Intervention: Radiation therapy
Description: Radiation therapy on the CE marked and FDA approved MR-Linac

Intervention type: RADIATION
Intervention: Radiation therapy
Description: Radiation therapy on the CE marked and FDA approved MR-Linac

Intervention type: RADIATION
Intervention: Radiation therapy
Description: Radiation therapy on the CE marked and FDA approved MR-Linac

Intervention type: RADIATION
Intervention: Radiation therapy
Description: Radiation therapy on the CE marked and FDA approved MR-Linac

Intervention type: RADIATION
Intervention: Radiation therapy
Description: Radiation therapy on the CE marked and FDA approved MR-Linac

Intervention type: RADIATION
Intervention: Radiation therapy
Description: Radiation therapy on the CE marked and FDA approved MR-Linac